Semaglutida vs AOD-9604
Semaglutida is mainly studied for appetite control, metabolic regulation. while AOD-9604 is studied for body composition, lipid metabolism. The difference is in the mechanism and the evidence, not in which is "better": it depends on the goal.
| Semaglutida | AOD-9604 | |
|---|---|---|
| Category | Metabolic | Metabolic |
| Studied for | Appetite control, metabolic regulation. | Body composition, lipid metabolism. |
| How it acts | A molecule associated with the GLP-1 pathway, studied for its relationship with appetite control, satiety and glucose regulation. | A fragment derived from a portion of growth hormone, studied for its relationship with lipid-metabolism pathways. |
| Evidence level | Human trials available | Preclinical evidence only |
How they differ
Although sometimes mentioned together, Semaglutida and AOD-9604 do not target the same thing. Semaglutida: A molecule associated with the GLP-1 pathway, studied for its relationship with appetite control, satiety and glucose regulation. AOD-9604: A fragment derived from a portion of growth hormone, studied for its relationship with lipid-metabolism pathways.
See full entry: Semaglutida → · See full entry: AOD-9604 →
Want to truly understand it, not memorize it?
The course explains each peptide at a university level: how it acts, what outcomes are studied, what it combines with and when to pause. No doses: the protocol is defined by a professional.
See the course → Start with the free test →Frequently asked questions
What is the main difference between Semaglutida and AOD-9604?
Semaglutida targets appetite control, metabolic regulation. and AOD-9604 targets body composition, lipid metabolism. They act through different pathways, so the choice depends on your goal, not on which is "stronger".
Can they be studied together?
Combinations are studied by goal in the literature, but combining is not just adding: it changes the safety profile. What to combine and how is decided with a professional; here we only explain what each is studied for.
Which has more human evidence?
Based on the references we verified, Semaglutida has more human studies of this pair. Each one's evidence level is in the table above, and the references with their PMID are at the end.
Other comparisons
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Semaglutida vs AOD-9604 or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
References
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
Some title in this list contains a figure, because that is how the study was published and we reproduce titles verbatim: trimming them would make the citation impossible to verify. A title is not a protocol. What amount suits a particular person is decided by a professional who knows their case, never by the headline of a trial.
- Once-Weekly Semaglutide in Adults with Overweight or Obesityhuman N Engl J Med · 2021 · PMID 33567185 →
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialhuman Lancet · 2021 · PMID 33667417 →
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trialhuman JAMA · 2021 · PMID 33755728 →
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trialhuman Nat Med · 2022 · PMID 36216945 →
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormonepreclinical Horm Res · 2000 · PMID 11146367 →
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragmentpreclinical Int J Obes Relat Metab Disord · 2001 · PMID 11673763 →
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out micepreclinical Endocrinology · 2001 · PMID 11713213 →
- AOD-9604 Metabolicreview Curr Opin Investig Drugs · 2004 · PMID 15134286 →
Educational content. It does not include doses, protocols or preparation: that is defined by a professional.